Venture Capital News: ReEmerge Launches With $37M Series A
2026-09-16
Tweet
EDINA, MN, ReEmerge, a private MedTech company innovating a new way to address cognitive impairment, has launched from stealth following the close of an oversubscribed $37 million Series A financing.
The proceeds will support an upcoming clinical study that will evaluate ReEmerge's proprietary Cognitive Network Restoration Therapy (CNRT) in its first clinical indication, traumatic brain injury (TBI), while advancing technology development, expanding clinical and regulatory operations, and preparing the platform for future indications. U.S. Venture Partners (USVP) and Santé co-led the round, with significant participation from Oxford Science Enterprises, 415 Capital, IAG Capital Partners, The Vertical Group, and Dendrion Ventures.
ReEmerge is innovating a new way to approach chronic cognitive impairment. Developed under an exclusive licensing agreement with Cornell University, the company's novel Cognitive Network Restoration Therapy (CNRT) precisely targets neural networks disrupted by brain injury that drive underactive but viable neural circuits. By restoring function across these existing but underperforming networks, CNRT aims to reverse cognitive deficits and restore agency and personhood.
ReEmerge is innovating a new way to approach chronic cognitive impairment. Developed under an exclusive licensing agreement with Cornell University, the company's novel Cognitive Network Restoration Therapy (CNRT) precisely targets neural networks disrupted by brain injury that drive underactive but viable neural circuits. By restoring function across these existing but underperforming networks, CNRT aims to reverse cognitive deficits and restore agency and personhood.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
